Drug products: ANORO ELLIPTA, Incruse Ellipta, Trelegy Ellipta
ATC code: R03AL03, R03AL08, R03BB07
Substances: umeclidinium, umeclidinium bromide
Limited data from controlled trials with umeclidinium, does not suggest any notable difference in the effect or pharmacokinetics between men and women.
COPD (chronic obstructive pulmonary disease) affects more women than men and women often get a more serious and rapidly progressive disease .
Population pharmacokinetic analysis (69% male) showed no evidence of a clinically significant sex difference in systemic exposure of umeclidinium .
Population pharmacokinetic analysis (69% male) showed no evidence of a clinically significant sex difference in effect .
No studies with a clinically relevant sex analysis regarding the adverse effects of umeclidinium have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2020-11-02
Reviewed by: Diana Rydberg, Carl-Olav Stiller
Approved by: Karin Schenck-Gustafsson